Vetter dual-chamber technology
For complex compounds that require lyophilization, Vetter offers two efficient and user-friendly systems: the dual-chamber Vetter Lyo-Ject® syringe and dual-chamber V-LK® cartridge.
For complex compounds that require lyophilization, Vetter offers two efficient and user-friendly systems: the dual-chamber Vetter Lyo-Ject ® syringe and dual-chamber V-LK ® cartridge. Lyophilized drug resides in one chamber; diluent in the other. The drug is reconstituted just prior to administration in a few simple steps.
Competitive advantages
- Product differentiation in a competitive arena, whether at initial launch or as part of a product lifecycle management strategy
- Market opportunity in a growing homecare sector, as patients and caregivers seek drug-delivery systems easy and safe enough to use independently
- Increased API yield, due to reduced overfill requirements
Dosage forms:
In addition to lyophilized-drug/diluent combinations, dual-chamber systems may also be used for liquid/liquid or powder/liquid drug combinations that require separation until point of use.
Sizes:
Dual-chamber syringe: in 1 ml, 2.5 ml and 5 ml sizes, covering fill volumes of 0.1 ml - 5 ml per chamber
Dual-chamber cartridge: in 1.5 ml size, covering fill volumes of 0.1 ml - 1.4 ml (first chamber) and 0.1 ml - 1.3 ml (second chamber)
For US inquiries please contact
+1-847-581-6888 or infoUS@vetter-pharma.com
For EU inquiries please contact
+49-751-3700-0 or info@vetter-pharma.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
